Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 25:9:921378.
doi: 10.3389/fcvm.2022.921378. eCollection 2022.

Role of sex on the efficacy of pharmacological and non-pharmacological treatment of heart failure with reduced ejection fraction: A systematic review

María Ascensión Sanromán Guerrero  1 , Sonia Antoñana Ugalde  1 , Elena Hernández Sánchez  1 , Susana Del Prado Díaz  1 , Marta Jiménez-Blanco Bravo  1 , David Cordero Pereda  1 , José Luis Zamorano Gómez  1 , Jesús Álvarez-García  1
Affiliations

Role of sex on the efficacy of pharmacological and non-pharmacological treatment of heart failure with reduced ejection fraction: A systematic review

María Ascensión Sanromán Guerrero et al. Front Cardiovasc Med. .

Abstract

Background: Heart Failure (HF) is a growing epidemic with a similar prevalence in men and women. However, women have historically been underrepresented in clinical trials, leading to uneven evidence regarding the benefit of guideline-directed medical therapy (GDMT). This review aims to outline the sex differences in the efficacy of pharmacological and non-pharmacological treatment of HF with reduced ejection fraction (HFrEF).

Methods and results: We conducted a systematic review via Medline from inception to 31 January 2022, including all randomized clinical trials published in English including adult patients suffering HFrEF that reported data on the efficacy of each drug. Baseline clinical characteristics, primary outcomes, and sex-specific effects are summarized in tables. The systemic review has been conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. In total, 29 articles were included in the systematic review. We observed that the proportion of women enrolled in clinical trials was generally low, the absence of a prespecified analysis of efficacy by sex was frequent, and the level of quality of evidence on the efficacy of GDMT and implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT-) in women was relatively poor.

Conclusions: Sex influences the response to treatment of patients suffering from HFrEF. All the results from the landmark randomized clinical trials are based on study populations composed mainly of men. Further studies specifically designed considering sex differences are warranted to elucidate if GDMT and new devices are equally effective in both sexes.

Keywords: gender; heart failure; sex; sex differences; women.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow-chart of the study selection.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Italian Association of Hospital Cardiologists Position Paper 'Gender discrepancy: time to implement gender-based clinical management'.
    Lucà F, Pavan D, Gulizia MM, Manes MT, Abrignani MG, Benedetto FA, Bisceglia I, Brigido S, Caldarola P, Calvanese R, Canale ML, Caretta G, Ceravolo R, Chieffo A, Chimenti C, Cornara S, Cutolo A, Di Fusco SA, Di Matteo I, Di Nora C, Fattirolli F, Favilli S, Francese GM, Gelsomino S, Geraci G, Giubilato S, Ingianni N, Iorio A, Lanni F, Montalto A, Nardi F, Navazio A, Nesti M, Parrini I, Pilleri A, Pozzi A, Rao CM, Riccio C, Rossini R, Scicchitano P, Valente S, Zuccalà G, Gabrielli D, Grimaldi M, Colivicchi F, Oliva F. Lucà F, et al. Eur Heart J Suppl. 2024 May 16;26(Suppl 2):ii264-ii293. doi: 10.1093/eurheartjsupp/suae034. eCollection 2024 Apr. Eur Heart J Suppl. 2024. PMID: 38784671 Free PMC article.

References

    1. Seferović PM, Vardas P, Jankowska EA, Maggioni AP, Timmis A, Milinković I, et al. . The heart failure association atlas: heart failure epidemiology and management statistics 2019. Eur J Heart Fail. (2021) 23:906–14. 10.1002/ejhf.2143 - DOI - PubMed
    1. Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, et al. . Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. (2018) 391:572–80. 10.1016/S0140-6736(17)32520-5 - DOI - PMC - PubMed
    1. Tromp J, Ouwerkerk W, Veldhuisen DJ., van Hillege HL, Richards AM, Meer P, van der, et al. . A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction. JACC Heart Fail. (2022) 10:73–84. 10.1016/j.jchf.2021.09.004 - DOI - PubMed
    1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. . 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. (2021) 42:3599–726. - PubMed
    1. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. . 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Card Fail. (2022) 28:810–30. 10.1016/j.cardfail.2022.02.009 - DOI - PubMed

Publication types